SESamia Esmat

Samia Esmat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samia Esmat has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing the content validity of the 2015 core domain set for vitiligo clinical trials: preliminary investigations for developing an updated version

    by Jolien Duponselle, Reinhart Speeckaert, Albert Wolkerstorfer, Julien Seneschal, Amit G Pandya, Iltefat Hamzavi, Amit Garg, Sandrine Herbelet, Liesbeth Delbaere, Nicoline Post, et al.

    Background: The 2015 core domain set (CDS) for vitiligo defines outcomes for clinical trials, comprising three essential and four recommended outcome domains/domain items. Periodic reassessment is required to ensure its continued relevance. Objectives: To evaluate the content validity (relevance, comprehensiveness and comprehensibility) of the 2015 vitiligo CDS to inform a consensus-based update as part of a core outcome set, including core outcomes and core measurement instruments. Methods: A roundtable discussion and three surveys reassessed the 2015 vitiligo CDS regarding relevance (≥ 70% agreement for ‘essential’), comprehensiveness (identification of missing domain items) and comprehensibility (clarity of terminology and descriptions). Results: Fifty-three patients with vitiligo (group 1) and 37 experts (36 dermatologists and 1 researcher; group 2) participated. Two previously essential domains (‘Repigmentation’ and ‘Side effects/harms’) were re-endorsed as essential by both groups. ‘Maintenance of gained repigmentation’ was rated essential by patients only. Among previously recommended domains, ‘Quality of life’ was considered essential by both groups, whereas ‘Cosmetic acceptability of repigmentation’ and ‘Cessation of spreading of vitiligo’ were rated essential by patients only. ‘Tolerability/burden of treatment’ was not considered essential by either group. Frequently suggested missing items (outcomes and contextual factors) included psychological impact, treatment session duration, overall treatment duration, treatment costs, patient education and evaluation of associated auto­immune diseases. Proposed updates included refining domain terminology (e.g. vitiligo-specific/health-related quality of life; replacing ‘harms’ with ‘adverse events’) and addressing feasibility-related timeframes. Conclusions: While the 2015 vitiligo CDS retains content validity for several domains, meaningful updates are warranted. These findings will inform the development of a revised and updated CDS.

  • The Safety of Melasma Treatment in Vitiligo Patients: An International E‐Delphi Study

    by Marwa Abdallah, Khaled Ezzedine, Thierry Passeron, Viktoria Eleftheriadou, Laila Benzekri, Caio Cesar Silva de Castro, Nada Elbuluk, Samia Esmat, Andrea Tovar‐Garza, Iltefat H. Hamzavi, et al.

    Vitiligo and melasma frequently coexist, creating a treatment dilemma, since agents effective for one condition can destabilize the other, and no consensus currently exists on safe management. We conducted a scoping literature review (through June 2023) on treatment of patients with concomitant vitiligo and melasma, followed by a two‐round international e‐Delphi survey (22 experts from 14 countries; consensus defined as ≥ 70% agreement) and a final online consensus meeting. Only one study supported the safe use of oral tranexamic acid for melasma in vitiligo patients. Expert consensus favored prioritizing vitiligo treatment, particularly when active, while incorporating patient's preferences. Targeted phototherapy is suitable for localized facial lesions of vitiligo, and non‐facial vitiligo can be treated alongside melasma after covering the face. Topical calcineurin inhibitors, ruxolitinib, tretinoin, corticosteroids, and oral tranexamic acid can be used. Lasers and chemical peels were recommended only with caution by experienced pigment specialists. Until there is enough scientific evidence, hydroquinone would be replaced by other safer cosmetic lightening agents (e.g., niacinamide, ascorbic acid, thiamidol, melasyl), which show comparable efficacy with less theoretical risk. This first international consensus offers practical, patient‐centered guidance for managing coexisting vitiligo and melasma, emphasizing individualized, disease‐activity‐based treatment sequencing. Trial Registration: PROSPERO reference number: RD42023395586 Significance . Depigmenting agents used for melasma inhibit melanogenesis, a mechanism that can further compromise the already‐stressed melanocyte populations characteristic of vitiligo. This consensus gives clinicians an expert‐informed pathway through a common but understudied comorbidity. It also identifies a clear research gap: controlled, mechanistic comparisons of hydroquinone against newer tyrosinase inhibitors specifically in vitiligo‐prone skin are still lacking.

  • Evaluation of needling/microneedling as an adjunct to phototherapy in the treatment of stable acral vitiligo: a comparative clinical and immunohistochemical study

    by Samia Esmat, Magda I. Assaf, Riham Mohye Eldeen, Heba I. Gawdat, Dina G., Dina G. Saadi

    To evaluate the efficacy and tolerability of needling/microneedling as an adjunct to NB-UVB phototherapy in the treatment of stable refractory patches of acral vitiligo, based upon clinical and imm...


  • Differentiating active from stable vitiligo: The role of dermoscopic findings and their relation to CXCL10

    by Sarah Ibrahim, Rehab A. Hegazy, Heba I. Gawdat, Samia Esmat, Esraa Mahmoud, Laila Rashed, Amira Aly Hegazy, Dina G. Saadi

    Background: Distinguishing vitiligo activity/stability status is pivotal in the management of patients with vitiligo. CXCL10 is a chemokine released in the tissues and sera of patients with vitiligo and an indicator of disease activity.Aim: This study aimed to assess the role of dermoscopy in detecting active and stable vitiligo by comparing the dermoscopic signs in vitiligo with Vitiligo Disease Activity Score (VIDA), clinical activity, and CXCL10 activity.Methods: Ninety‐seven patients with vitiligo were enrolled in this cross‐sectional study. Vitiligo activity/stability was assessed using VIDA scores, clinical examination, dermoscopy, and serum CXCL10 levels measured by enzyme‐linked immunosorbent assay technique. Dermoscopic scores were calculated using BPLeFoSK score.Results: The dermoscopic score was concordant with the VIDA score in 83.5% of patients (n = 81), clinical assessment in 97.9% (n = 95), and serum CXCL10 level in 70.1% (n = 68). Dermoscopic signs of ill‐defined border, satellite lesions, and micro‐Koebner and starburst appearance were more common in active vitiligo, while a well‐defined border was more common in stable lesions.Conclusion: Dermoscopic examination is a practical, reliable, noninvasive, semi‐objective tool in the assessment of vitiligo activity/stability that helps reach an informed decision on the disease status to choose the appropriate therapeutic modality.


  • Combining Low Power Fractional CO2 With QS‐NdYAG Toning in the Treatment of Melasma Reduces the Incidence of Punctate Leukoderma

    by Samia Esmat, Amany Z. Elramly, Dina Shahin, Rana F. Hilal

    Background and Objectives: Q‐switched Nd:YAG (QS‐Nd:YAG) toning (low fluence, large spot size, and high frequency) has been used successfully for the treatment of melasma, especially in dark skin phototypes. Punctate leukoderma was found to be a frequent complication that reduced the safety of this procedure. Combining low power fractional CO2 laser, which is another effective melasma laser therapy, might improve the efficacy and safety of this procedure. The aim of this study was to evaluate the effect of combining low power fractional CO2 laser with QS‐Nd:YAG toning in the treatment of melasma.Study Design/Materials and Methods: A randomized comparative split‐face study included a total of 30 patients with bilateral, symmetrical melasma. All patients received QS‐Nd:YAG toning on one randomly selected side of the face, while the other side randomly received either low power fractional CO2 alone (group A) or combined QS‐Nd:YAG toning with low power fractional CO2 (group B). QS‐Nd:YAG toning sessions were scheduled every two weeks for nine consecutive sessions, and low power fractional CO2 sessions were received every 4 weeks for three consecutive sessions. The assessment was done using the modified melasma area and severity index (mMASI) score, spectrophotometry (melanin index [MI] and erythema index [EI]), photography, blinded physician assessment, and patient satisfaction (at baseline, 1 week and 8‐12 weeks after the last treatment sessions).Results: A significant reduction in the mMASI score and MI was obtained with all treatment regimens. On comparing different modalities, group A reduction in mMASI and MI was significantly greater on the side receiving QS‐ND:YAG toning (64.03% and 8.27%, respectively), than the side receiving low power fractional CO2 laser alone (36.02%. 2.64%, respectively). On the other hand, reduction of mMASI score and MI showed no statistical significance between the side receiving QS‐Nd:YAG toning alone and the combined modality. Punctate leukoderma occurred in four cases (13%) on the side receiving QS‐Nd:YAG toning.Conclusion: QS‐Nd:YAG toning is significantly more effective than low power fractional CO2 in the treatment of melasma when used separately. Although combining low power fractional CO2 with QS‐Nd:YAG toning does not increase its efficacy, it minimizes the incidence of the undesirable punctate leukoderma complication and achieves lower recurrence. This combination can thus be recommended as a safe and effective measure for the treatment of melasma. © 2021 Wiley Periodicals LLC.


  • Proceeding Report of the Second Vitiligo International Symposium—November 9–10, 2018, Detroit, Michigan, USA

    by Alexis B. Lyons, Deepti Ghia, Marwa Abdallah, Zalfa Abdel‐Malek, Samia Esmat, Khaled Ezzedine, Pearl Grimes, John E. Harris, Harvey Lui, Prashiela Manga, et al.